US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global X China Biotech Innovation ETF

6.64

0.0000

Volume:- -

Turnover:- -

Market Cap:1.39M

PE:- -

High:6.64

Open:6.64

Low:6.64

Close:6.64

52wk High:6.64

52wk Low:6.64

Shares:210.00K

Float Shares:210.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Cosunter Pharmaceutical Wins Breakthrough Therapy Status for CHB Drug in China

MT Newswires Live

GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials

MT Newswires Live

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHB\",,,,,undefined,":{"symbol":"CHB","market":"US","secType":"STK","nameCN":"Global X China Biotech Innovation ETF","latestPrice":6.64,"timestamp":1739998800000,"preClose":6.64,"halted":0,"volume":0,"delay":0,"floatShares":210000,"shares":210000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"08-21 15:04:44 EDT","open":6.64,"high":6.64,"low":6.64,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1755806400000},"marketStatusCode":2,"adr":0,"listingDate":1601006400000,"exchange":"NASDAQ","adjPreClose":6.64,"sharesOutstanding":210000,"nav":6.72,"aum":1412042.9,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHB\",,,,,undefined,":{"symbol":"CHB","floatShares":210000,"roa":"--","roe":"--","lyrEps":0,"shares":210000,"dividePrice":0,"high":6.64,"amplitude":0,"preClose":6.64,"low":6.64,"week52Low":6.64,"pbRate":"--","week52High":6.64,"institutionHeld":0,"latestPrice":6.64,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":6.64,"prevYearClose":6.64,"prevWeekClose":6.64,"prevMonthClose":6.64,"prevQuarterClose":6.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-20","symbol":"CHB","reason":null,"defaultRemindTime":1708439400000,"announcedDate":"2024-02-16","type":"delisting","dateTimestamp":1708405200000},{"date":"2023-12-28","symbol":"CHB","amount":0.001878,"announcedDate":"2023-12-27","type":"dividend","market":"US","newRecordDate":"2023-12-29","defaultRemindTime":1703773800000,"name":"Global X China Biotech Innovation ETF","recordDate":"2024-01-08","payableDate":"2023-12-29","currency":"USD","dateTimestamp":1703739600000,"payDate":"2024-01-08"},{"date":"2023-06-29","symbol":"CHB","amount":0.037027,"announcedDate":"2023-06-28","type":"dividend","market":"US","newRecordDate":"2023-06-30","defaultRemindTime":1688045400000,"name":"Global X China Biotech Innovation ETF","recordDate":"2023-07-10","payableDate":"2023-06-30","currency":"USD","dateTimestamp":1688011200000,"payDate":"2023-07-10"},{"market":"US","date":"2022-06-29","symbol":"CHB","amount":0.019889,"defaultRemindTime":1656509400000,"name":"Global X China Biotech Innovation ETF","recordDate":"2022-07-08","payableDate":"2022-06-30","currency":"USD","type":"dividend","dateTimestamp":1656475200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHB\",market:\"US\",,,undefined,":[{"executeDate":"2022-06-29","recordDate":"2022-06-30","paymentDate":"2022-07-08","value":0.019889,"currency":"USD"},{"executeDate":"2023-06-29","recordDate":"2023-06-30","paymentDate":"2023-07-10","value":0.037027,"currency":"USD"},{"executeDate":"2023-12-28","recordDate":"2023-12-29","paymentDate":"2024-01-08","value":0.001878,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550859429","title":"Cosunter Pharmaceutical Wins Breakthrough Therapy Status for CHB Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2550859429","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550859429?lang=en_us&edition=fundamental","pubTime":"2025-07-11 14:34","pubTimestamp":1752215695,"startTime":"0","endTime":"0","summary":"Fujian Cosunter Pharmaceutical  secured breakthrough therapy designation in China for its oral HBsAg inhibitor GST-HG131, its second chronic hepatitis B  drug to earn this status after GST-HG141.Phase two data showed 87% average HBsAg reduction, with potential for functional cure when combined with GST-HG141, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 5% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300436","CHB"],"gpt_icon":0},{"id":"2538173770","title":"GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2538173770","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538173770?lang=en_us&edition=fundamental","pubTime":"2025-05-26 16:37","pubTimestamp":1748248663,"startTime":"0","endTime":"0","summary":"GNI Group   core subsidiary Gyre Therapeutics has priced a public offering of 2.22 million common shares at $9.00 per share, aiming to raise approximately $20 million before underwriting discounts and other expenses.The proceeds from this offering, combined with existing cash and operational cash flow, are earmarked mainly to advance the Phase 2 clinical trial of F351 for liver fibrosis caused by MASH in the United States, according to its filing last Friday.This public offering, including an overallotment option for an additional 333,333 shares, is expected to close on May 27.While the number of outstanding shares may increase by up to 2.56 million shares, potentially diluting GNI Group's ownership from approximately 83.03% to 80.69%, this will not alter the scope of consolidation.In a separate filing, the group said Gyre Therapeutics has met the primary endpoint in a pivotal Phase 3 clinical trial in China, demonstrating the efficacy and safety of F351  for treating liver fibrosis in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHB"],"gpt_icon":0},{"id":"2529147549","title":"Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529147549","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529147549?lang=en_us&edition=fundamental","pubTime":"2025-04-23 14:01","pubTimestamp":1745388060,"startTime":"0","endTime":"0","summary":"WARMINSTER, Pa., April 23, 2025  -- Arbutus Biopharma Corporation  , a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver  Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands.The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies, Unapproved Therapies or Strategies session on May 8, 2025, from 8:30 am – 5:00 pm CET.This will also be featured in the Poster Tour: Viral Hepatitis, on Thursday, May 8, 2025, at 16:22 CEST.Abstract Number: 1978Title: Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small-molecule PD-L1 inhibitor, in healthy and chronic hepatitis B subjectsPresenter: Prof. Edward J. GanePresentation Date: May 8, 2025Key Findings: Single doses of AB-101 up to 40 mg and re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arbutus-present-imdusiran-ab-101-060100034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4598","BK4135","IFN","LU0128526141.USD","BK4139","BK4523","ABUS","LU0029874061.USD","BK4590","CHB","BK4141","AB","NA"],"gpt_icon":0},{"id":"2522304112","title":"IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304112","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304112?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:31","pubTimestamp":1743078660,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive rights to market its wholly owned drug Tryngolza outside the United States .The FDA recently approved Tryngolzafor treating familial chylomicronemia syndrome , a rare genetic disease marked by extremely elevated triglyceride levels. This nod makes the drug the first approved treatment for FCS in the country.Italso marks Ionis’ first independent commercial launch. A regulatory filing for this FCS drug is currently under review by the EMA, with a final decision expected later this year.Per the deal terms, Sobi will be responsible for all future regulatory filings and commercialization activities for the drug in ex-U.S.geographies exceptCanada andChina. Ionis will continue to market the drug in the United States independently.In consideration of granting these rights, Ionis will receive an undisclosed upfront payment and be eligible for milestone payments. The company w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ions-licenses-ex-u-rights-123100545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHB","GSK.UK","LU0889565916.HKD","LU2462157665.USD","GSK","BK4568","BIIB","IE00B19Z9Z06.USD","LU2236285917.USD","BK4588","BK4139","LU2456880835.USD","LU0234570918.USD","LU1829250122.USD","LU2417539215.USD","BK4532","AZN","BK4007","IONS","LU0320765992.SGD","BK4585","IE00B894F039.SGD","LU0109394709.USD","IE00B19Z9P08.USD","BK4533"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CHB\",params:#limit:6,delay:false,,,undefined,":[]}}